{
  "abstract": "Abstract T cell engagers (TCEs) recruit T cells to the tumor microenvironment (TME) to induce antitumor immune responses. TCEs have demonstrated promising clinical responses in patients with metastatic castration-resistant prostate cancer and have advanced into phase 3 clinical trials. Here we provide an overview of the mechanisms of action of TCEs, including both CD3-targeted and CD28-targeted agents, and review the clinical development of these agents for prostate cancer. We propose a path forward for TCEs in prostate cancer, in which innovative clinical trials will facilitate a biological understanding of mechanisms of efficacy and toxicity to inform: (1) development of predictive biomarkers for patient selection; (2) rational combination strategies; and (3) targeted treatments for toxicity management, ultimately delivering broad clinical benefit for patients with lethal prostate cancer.",
  "authors": [
    {
      "affiliations": [
        "The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"
      ],
      "name": "Sumit K Subudhi"
    },
    {
      "affiliations": [
        "The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"
      ],
      "name": "Bilal A Siddiqui"
    },
    {
      "affiliations": [
        "Thomas Jefferson University, Philadelphia, Pennsylvania, USA"
      ],
      "name": "Kevin K Zarrabi"
    },
    {
      "affiliations": [
        "Thomas Jefferson University, Philadelphia, Pennsylvania, USA"
      ],
      "name": "William K Kelly"
    },
    {
      "affiliations": [
        "Johnson & Johnson Innovative Medicine, Raritan, New Jersey, USA"
      ],
      "name": "Charles G Drake"
    }
  ],
  "title": "The path forward for T cell engagers in patients with prostate cancer",
  "uid": "a7c4fd85-c0c5-542c-9f3f-9401e205c247"
}